{"id":536240,"date":"2021-09-09T08:04:07","date_gmt":"2021-09-09T12:04:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/"},"modified":"2021-09-09T08:04:07","modified_gmt":"2021-09-09T12:04:07","slug":"mereo-biopharma-to-participate-in-three-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/","title":{"rendered":"Mereo BioPharma to Participate in Three Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LONDON and REDWOOD CITY, Calif., Sept.  09, 2021  (GLOBE NEWSWIRE) &#8212; Mereo BioPharma Group plc (NASDAQ: MREO) (\u201cMereo\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced senior management\u2019s participation in three upcoming investor conferences:<\/p>\n<p align=\"justify\">\n        <strong>Morgan Stanley 19th Annual Global Healthcare Conference<\/strong><br \/>\n        <br \/>1&#215;1 meetings, September 13 \u2013 14, 2021<\/p>\n<p align=\"justify\">\n        <strong>SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event<\/strong><br \/>\n        <br \/>1&#215;1 meetings, September 22-23, 2021<\/p>\n<p align=\"justify\">\n        <strong>Cantor Fitzgerald Virtual Global Healthcare Conference <\/strong><br \/>\n        <br \/>Fireside Chat Thursday, September 30, 2021 at 9:30am ET<\/p>\n<p align=\"justify\">A live audio webcast of the Cantor Fitzgerald fireside chat can be accessed through the Investors section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4JfZFQsoEZDyDroH1EA5nB6mleUEXFDgZHCg-8iRe0uagMk21ZIylZ03CElM9MSo9K2wvdQaBC41Ypg5md1RP8vXhhV1gBFdUa5GT1RNFAqeeftiFvAol7OC1bvDRdv6\" rel=\"nofollow noopener\" target=\"_blank\">www.mereobiopharma.com\/investors<\/a>. An archived replay of the webcast will be available on the Company\u2019s website for two weeks following the live presentation.<\/p>\n<p align=\"justify\">\n        <strong>About Mereo BioPharma<\/strong><br \/>\n        <br \/>Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. The Company has developed a portfolio of six clinical stage product candidates. Mereo\u2019s lead oncology product candidate, etigilimab (Anti-TIGIT), has recently advanced into an open label Phase 1b\/2 basket study evaluating Anti-TIGIT in combination with an anti-PD-1 in a range of tumor types including three rare tumors and a number of gynecological carcinomas including cervical, ovarian and endometrial carcinomas. The Company\u2019s second oncology product, navicixizumab, for the treatment of late line ovarian cancer, has completed a Phase 1 study and has been partnered with OncXerna Therapeutics, Inc., formerly Oncologie, Inc. The Company has two rare disease product candidates: alvelestat for the treatment of severe Alpha-1 antitrypsin deficiency (AATD), which is being investigated in an ongoing Phase 2 proof-of-concept study in the U.S. and Europe, for which the Company expects to report top line data in late 2021, and setrusumab for the treatment of osteogenesis imperfecta (OI). In September 2020, the FDA granted Rare Pediatric Disease designation to setrusumab for the treatment of OI. In December 2020, the Company signed a license and collaboration agreement for setrusumab in OI with Ultragenyx Pharmaceutical Inc.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements.\u201d All statements other than statements of historical fact contained in this press release are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), and Section 21E of the United States Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d). Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. Forward-looking statements are often identified by the words \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201cintend,\u201d \u201cforesee,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cmay,\u201d \u201cestimate,\u201d \u201coutlook\u201d and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company\u2019s current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.<\/p>\n<p align=\"justify\">All of the Company\u2019s forward-looking statements involve known and unknown risks and uncertainties some of which are significant or beyond its control and assumptions that could cause actual results to differ materially from the Company\u2019s historical experience and its present expectations or projections. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company\u2019s business, including those described in the \u201cRisk Factors\u201d section of its latest Annual Report on Form 20-F, reports on Form 6-K and other documents furnished or filed from time to time by the Company with the SEC. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.<\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:30%;width:30%;min-width:30%;text-align: justify;vertical-align: middle;vertical-align: middle\">\n            <strong>Mereo BioPharma Contacts:<\/strong>\n          <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0\u00a0<\/td>\n<td style=\"max-width:69%;width:69%;min-width:69%;text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\n            <strong>Mereo<\/strong>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\n            <strong>+44 (0)333 023 7300<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">Denise Scots-Knight, Chief Executive Officer<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">Christine Fox, Chief Financial Officer<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\n            <strong>Burns McClellan (Investor Relations Adviser to Mereo)<\/strong>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\n            <strong>+01 212 213 0006<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">Lee Roth<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\n            <strong>Investors<\/strong>\n          <\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\u00a0\u00a0<\/td>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: middle\">\n            <a href=\"mailto:investors@mereobiopharma.com\" rel=\"nofollow noopener\" target=\"_blank\">investors@mereobiopharma.com<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjQ3MyM0Mzk1NTk2IzIwOTg3OTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmE3YTY0MzYtNzZjYi00OTMyLWExZjEtMjJmMTUzZmEyOWFhLTExMTAzNjg=\/tiny\/Mereo-BioPharma-Group-plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON and REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Mereo BioPharma Group plc (NASDAQ: MREO) (\u201cMereo\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced senior management\u2019s participation in three upcoming investor conferences: Morgan Stanley 19th Annual Global Healthcare Conference 1&#215;1 meetings, September 13 \u2013 14, 2021 SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event 1&#215;1 meetings, September 22-23, 2021 Cantor Fitzgerald Virtual Global Healthcare Conference Fireside Chat Thursday, September 30, 2021 at 9:30am ET A live audio webcast of the Cantor Fitzgerald fireside chat can be accessed through the Investors section of the Company\u2019s website at www.mereobiopharma.com\/investors. An archived replay of the webcast will be available on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mereo BioPharma to Participate in Three Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-536240","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mereo BioPharma to Participate in Three Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mereo BioPharma to Participate in Three Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON and REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Mereo BioPharma Group plc (NASDAQ: MREO) (\u201cMereo\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced senior management\u2019s participation in three upcoming investor conferences: Morgan Stanley 19th Annual Global Healthcare Conference 1&#215;1 meetings, September 13 \u2013 14, 2021 SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event 1&#215;1 meetings, September 22-23, 2021 Cantor Fitzgerald Virtual Global Healthcare Conference Fireside Chat Thursday, September 30, 2021 at 9:30am ET A live audio webcast of the Cantor Fitzgerald fireside chat can be accessed through the Investors section of the Company\u2019s website at www.mereobiopharma.com\/investors. An archived replay of the webcast will be available on &hellip; Continue reading &quot;Mereo BioPharma to Participate in Three Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-09T12:04:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjQ3MyM0Mzk1NTk2IzIwOTg3OTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mereo BioPharma to Participate in Three Upcoming Investor Conferences\",\"datePublished\":\"2021-09-09T12:04:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\\\/\"},\"wordCount\":712,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjQ3MyM0Mzk1NTk2IzIwOTg3OTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\\\/\",\"name\":\"Mereo BioPharma to Participate in Three Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjQ3MyM0Mzk1NTk2IzIwOTg3OTc=\",\"datePublished\":\"2021-09-09T12:04:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjQ3MyM0Mzk1NTk2IzIwOTg3OTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMjQ3MyM0Mzk1NTk2IzIwOTg3OTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mereo BioPharma to Participate in Three Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mereo BioPharma to Participate in Three Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Mereo BioPharma to Participate in Three Upcoming Investor Conferences - Market Newsdesk","og_description":"LONDON and REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) &#8212; Mereo BioPharma Group plc (NASDAQ: MREO) (\u201cMereo\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced senior management\u2019s participation in three upcoming investor conferences: Morgan Stanley 19th Annual Global Healthcare Conference 1&#215;1 meetings, September 13 \u2013 14, 2021 SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases &amp; Genetic Medicines 1&#215;1 Event 1&#215;1 meetings, September 22-23, 2021 Cantor Fitzgerald Virtual Global Healthcare Conference Fireside Chat Thursday, September 30, 2021 at 9:30am ET A live audio webcast of the Cantor Fitzgerald fireside chat can be accessed through the Investors section of the Company\u2019s website at www.mereobiopharma.com\/investors. An archived replay of the webcast will be available on &hellip; Continue reading \"Mereo BioPharma to Participate in Three Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-09T12:04:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjQ3MyM0Mzk1NTk2IzIwOTg3OTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mereo BioPharma to Participate in Three Upcoming Investor Conferences","datePublished":"2021-09-09T12:04:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/"},"wordCount":712,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjQ3MyM0Mzk1NTk2IzIwOTg3OTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/","name":"Mereo BioPharma to Participate in Three Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjQ3MyM0Mzk1NTk2IzIwOTg3OTc=","datePublished":"2021-09-09T12:04:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjQ3MyM0Mzk1NTk2IzIwOTg3OTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMjQ3MyM0Mzk1NTk2IzIwOTg3OTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mereo-biopharma-to-participate-in-three-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mereo BioPharma to Participate in Three Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=536240"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/536240\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=536240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=536240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=536240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}